Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema a ...

The following is a summary of “Effect of spesolimab on sustained disease control in patients with generalized pustular ...

BAGSVAERD, Denmark I March 10, 2025 I Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme.

Novo Nordisk (NVO) faces a 6% premarket drop after clinical trial results for its obesity drug CagriSema fell below ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

The study used innovative technology that maps RNA molecules which are the basis for translating the genome into proteins.

Not all body fat is the same when it comes to health and weight loss. Fat that sits just under the skin, called subcutaneous ...

High levels of “hidden” fat known as visceral fat may put you at higher risk for Alzheimer’s disease up to two decades before ...

Two people with the same BMI can have completely different metabolic risks depending on their visceral fat distribution.